26th Annual Meeting and Education Day of the Society for Neuro-Oncology November 18 - 21, 2021
IMO Kazia management will wait for the final data from paxalisib phase2 Kazia / Danna-Farber GBM trial results, and then submit a New Drug Application (NDA) submission, which may result in a faster product approval for paxalisib.
Regards.
- Forums
- ASX - By Stock
- KZA
- SNO 26th Annual Meeting
SNO 26th Annual Meeting, page-2
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online